Investors & News

Latest News

August 14, 2019
Stealth BioTherapeutics Reports First Half 2019 Financial Results And Recent Business Highlights
July 02, 2019
Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders
May 30, 2019
Stealth Biotherapeutics to Present at Upcoming Investor Conferences
All News

Stock Quote (MITO)

Share

Why invest?

Our Company

Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.

Our Programs

We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.

Our Pipeline

We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.

Latest Reports

March 14, 2019
6-K Report of Foreign Private Issuer
HTML
February 14, 2019
Stealth BioTherapeutics Prospectus
HTML
Reports

Latest Presentations

June 24, 2019
Investor Presentation June 2019
Presentations

Events

July 11, 2019
Stealth Biotherapeutics, Inc.'s KOL Breakfast
June 25, 2019
The BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference at 3:20 pm EDT
Financial Calendar
Media Relations

dna Communications
Lindsey Colegrove, 212-537-8771
media@stealthbt.com

Investor Inquiries
Stern IR
Lauren Stival, 212-362-1200
IR@stealthbt.com